Prophylaxis of venous thromboembolism in acutely ill medical patients;Profilaxis de la tromboembolia venosa en pacientes con procesos médicos agudos

Medicina Clinica

Volumn 126, Issue 19, 2006, Pages 754-756

  Rodríguez, Alexis ^a   Vallano, Antonio ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; PLACEBO;

CLINICAL TRIAL; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; META ANALYSIS; REVIEW; SEPTIC SHOCK; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 33745651843     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13088952     Document Type: Article

References (13)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126 Suppl:S338-400.
2. THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ. 1992;305:567-74.
3. Alonso Ortiz del Río C, Medrano Ortega FJ, Romero Alonso A, Villar Conde E, Calderón Sandubete E, Marín León I, et al. Guía PRETEMED 2003. Guía de profilaxis de enfermedad tromboembólica en patología médica. Córdoba: SADEMI; 2003.
4. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. A national clinical guidelines. Edinburgh: Royal College of Physicians; 2002. Disponible en: http: www.sign.ac.uk
5. Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. Q J Med. 2000;93:359-64.
6. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14-9.
7. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341:793-800.
8. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9.
9. Cohen AT, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Davidson BL, et al. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost. 2003;1 Suppl 1:[abstract P2046].
10. Cohen AD, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-9.
11. Wade WE, Chisholm MA. Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients. Thromb Res. 1999;94:65-8.
12. De Lissovoy G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am J Manag Care Care. 2002;8:1082-8.
13. Lamy A, Wang X, Kent R, Smith KM, Gafni A. Economic evaluation of the MEDENOX trial: a Canadian perspective. Can Respir J. 2002;9:169-77.